Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Emgality ® ▼ (galcanezumab)
Emgality® ▼ (galcanezumab): Use in Patients With COVID-19 (Coronavirus Disease 2019)
The use of galcanezumab in patients with COVID-19 has not been studied.
Eli Lilly and Company has not studied the use of galcanezumab in patients with COVID-19.
CGRP mAbs Have no Direct Specific Immunomodulatory Effect
The CGRP mAbs have been engineered to bind to either the CGRP peptide or receptor with high specificity and minimized interaction with the immune system.3-5 As CGRP is not an immune system target, CGRP mAbs have no direct immunomodulatory effect.
The use of galcanezumab is not associated with increased risk of infections or immunosuppression, nor are such events identified as important risks in the galcanezumab risk management plan.6
Published Literature Related to Use of CGRP Monoclonal Antibody Therapy in a Patient With COVID-19
There is limited published literature on the management of patients with migraine and COVID-19. As of the last revision date, the Spanish Society of Neurology's Headache Study Group has published their opinion that the currently available data do not suggest that interruption to standard headache therapies is warranted.7 In an editorial published in Headache, the authors recommend the use of migraine preventive therapies, which include CGRP mAbs, that allow for management of the patient in a telehealth setting.8
Infectious Disease Resources
For the most current information regarding the coronavirus, please refer to the WHO website:
1. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization. Accessed November 10, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it
2. Coronavirus. World Health Organization. Accessed November 10, 2020. https://www.who.int/health-topics/coronavirus#tab=tab_1
3. Raffaelli B, Reuter U. The biology of monoclonal antibodies: focus on calcitonin gene-related peptide for prophylactic migraine therapy. Neurotherapeutics. 2018;15(2):324-335. http://dx.doi.org/10.1007/s13311-018-0622-7
4. Silberstein S, Lenz R, Xu C. Therapeutic monoclonal antibodies: what headache specialists need to know. Headache. 2015;55(8):1171-1182. http://dx.doi.org/10.1111/head.12642
5. Levin M, Silberstein SD, Gilbert R, et al. Basic considerations for the use of monoclonal antibodies in migraine. Headache. 2018;58(10):1689-1696. http://dx.doi.org/10.1111/head.13439
7. Morollón N, Belvís R, De Dios A, et al. Standard headache and neuralgia treatments and SARS-CoV-2: opinion of the Spanish Society of Neurology's Headache Study Group. Neurología. 2020;35(9):628-632. http://dx.doi.org/10.1016/j.nrl.2020.07.007
8. Szperka CL, Ailani J, Barmherzig R, et al. Migraine care in the era of COVID-19: clinical pearls and plea to insurers. Headache. 2020;60(5):833-842. http://dx.doi.org/10.1111/head.13810
CGRP = calcitonin gene-related peptide
COVID-19 = coronavirus disease 2019
mAb = monoclonal antibody
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
WHO = World Health Organization
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: November 03, 2020